Closing a financing gap

    The Crossover strategy launched in April 2018, completing Sofinnova's investment platform by enabling it to invest across the life-sciences value chain, from seed stage to later-stage.

    We invest across all biotech sectors, focusing on companies with game-changing science that has initial proof of concept.

    CloseFundAMT
    2018Sofinnova Crossover I€445 million
    • Close: 2018

      Fund: Sofinnova Crossover I

      AMT: €445 million

    "Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."

    "Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."

    "It is exciting to help companies find that next gear of growth as they bring new medicines to market.”

    "The science in Europe is the same quality as any you'll find in the U.S."

    The
    Team

    Companies

    Fund iteration
    Status
    Deal lead

    Join our mailing list

    Keep up to date with our latest news.

    Required
    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.